OTCMKTS:PBSV Pharma-Bio Serv (PBSV) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free PBSV Stock Alerts $0.74 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.74▼$0.7450-Day Range$0.70▼$0.9652-Week Range$0.65▼$1.10VolumeN/AAverage Volume1,870 shsMarket Capitalization$16.88 millionP/E Ratio24.51Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Pharma-Bio Serv alerts: Email Address Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Pharma-Bio Serv Stock (OTCMKTS:PBSV)Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.Read More PBSV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBSV Stock News HeadlinesApril 26, 2024 | americanbankingnews.comPharma-Bio Serv (OTCMKTS:PBSV) Stock Passes Below Two Hundred Day Moving Average of $0.91April 25, 2024 | markets.businessinsider.comDeep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)May 2, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...April 25, 2024 | markets.businessinsider.comEQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché LaboratóriosApril 23, 2024 | markets.businessinsider.comBiomarin Pharmaceutical earnings preview: what Wall Street is expectingApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market ExpectationsApril 9, 2024 | tmcnet.comSanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com's Supplier Pre-assessment ProgramApril 3, 2024 | benzinga.comLooking Into Biomarin Pharmaceutical's Recent Short InterestMay 2, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...March 19, 2024 | finance.yahoo.comPBSV Releases Quarterly ResultsMarch 19, 2024 | seekingalpha.comPharma-Bio Serv reports Q1 resultsMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial OutlookMarch 4, 2024 | markets.businessinsider.comMaintaining Hold on BridgeBio Pharma Amidst Bayer Partnership and Market UncertaintiesFebruary 26, 2024 | marketwatch.comBioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- UpdateFebruary 23, 2024 | markets.businessinsider.comStrong Voxzogo Performance Underpins Buy Rating for BioMarin PharmaceuticalJanuary 30, 2024 | finance.yahoo.comPBSV Expands Margins and MarketsJanuary 28, 2024 | msn.comJubilant Pharma Plans Stake Sale in Sofie Biosciences Amid Merger DealJanuary 9, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth DriversJanuary 8, 2024 | seekingalpha.comBridgeBio Pharma's Robust Pipeline Could Benefit From A PartnerJanuary 3, 2024 | finance.yahoo.comPBSV Reward Shareholders with High YieldDecember 21, 2023 | finanznachrichten.dePharma-Bio Serv Inc.: Pharma-Bio Serv Announces Special DividendDecember 8, 2023 | msn.comAbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?November 28, 2023 | markets.businessinsider.comBioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In GermanyNovember 7, 2023 | markets.businessinsider.comPromising Future for BridgeBio Pharma: Lebovitz’s Buy Rating Backed by Potential Blockbusters and Pipeline AssetsNovember 6, 2023 | markets.businessinsider.comBridgeBio Pharma Receives Buy Rating Amid Promising Drug Pipeline Developments and Strong Financial PositionSeptember 15, 2023 | finance.yahoo.comPBSV Boosts Margins and Expands MarketsSeptember 14, 2023 | finance.yahoo.comPharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2023See More Headlines Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 2/15 Dividend1/29/2024Dividend Payable2/15/2024Last Earnings3/18/2024Today5/02/2024Next Earnings (Estimated)6/12/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Management consulting services Sub-IndustryN/A Current SymbolOTCMKTS:PBSV CUSIPN/A CIK1304161 Webwww.pharmabioserv.com Phone(787) 278-2709Fax787-796-5168Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio24.51 Forward P/E Ratio9.19 P/E GrowthN/ANet Income$1.31 million Net Margins4.05% Pretax Margin5.65% Return on Equity3.95% Return on Assets3.10% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio5.10 Sales & Book Value Annual Sales$16.98 million Price / Sales0.99 Cash Flow$0.07 per share Price / Cash Flow11.23 Book Value$0.70 per share Price / Book1.05Miscellaneous Outstanding Shares22,960,000Free Float20,162,000Market Cap$16.88 million OptionableNot Optionable Beta0.55 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Victor Sanchez (Age 53)CEO, President & President of European Operations Comp: $323.67kMr. Pedro J. Lasanta (Age 64)CFO, VP of Finance & Administration and Secretary Comp: $225.6kMs. Elizabeth Plaza (Age 60)Founder & Senior Strategic Consultant Comp: $69.92kMs. Miriam Marrero M.B.A.Human Resources ManagerKey CompetitorsCastellumNYSEAMERICAN:CTMGopher ProtocolOTCMKTS:GOPHATIFNASDAQ:ATIFRyvylNASDAQ:RVYLAeries TechnologyNASDAQ:AERTView All Competitors PBSV Stock Analysis - Frequently Asked Questions How have PBSV shares performed in 2024? Pharma-Bio Serv's stock was trading at $1.05 at the start of the year. Since then, PBSV stock has decreased by 30.0% and is now trading at $0.7350. View the best growth stocks for 2024 here. When is Pharma-Bio Serv's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our PBSV earnings forecast. How were Pharma-Bio Serv's earnings last quarter? Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) released its earnings results on Monday, March, 18th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.03. The business had revenue of $2.38 million for the quarter, compared to analysts' expectations of $5 million. Pharma-Bio Serv had a trailing twelve-month return on equity of 3.95% and a net margin of 4.05%. How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv? Pharma-Bio Serv announced a dividend on Thursday, December 21st. Stockholders of record on Tuesday, January 30th will be paid a dividend of $0.075 per share on Thursday, February 15th. The ex-dividend date is Monday, January 29th. Read our dividend analysis for PBSV. What other stocks do shareholders of Pharma-Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE). How do I buy shares of Pharma-Bio Serv? Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PBSV) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressYour bank is lying to you.MyBankTrackerForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma-Bio Serv, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.